# A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

> **NCT01470131** · PHASE3 · TERMINATED · sponsor: **AB Science** · enrollment: 147 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Masitinib
- **DRUG:** Placebo
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01470131
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2017-01-04
- **Final completion:** 2017-02-01
- **Target enrollment:** 147 (ACTUAL)
- **Why stopped:** Sponsor decision based on portfolio prioritization
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470131, "A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01470131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*